Can You Still Buy Merck Stock Today?
Bristol-Myers Squibb Company BMY
$62.14
▲ +0.00%
(+$0.00)
Index member:
S&P 500
💰 High Dividend
Open
$62.88
Prev Close
$62.14
Day Range
$61.80 – $63.06
52W Range
$45.27 – $68.64
Market Cap
$126.14B
P/E (TTM)
13.71
Beta
0.14
Div Yield
4.58%
EPS (TTM)
$4.51
📋 Company Profile
| Industry | Pharmaceuticals |
| Sector | Health Care |
| Country | US |
| Exchange | NEW YORK STOCK EXCHANGE, INC. |
| Currency | USD |
| IPO Date | 1980-03-17 |
| Shares Out. | 2,044,090,000 |
| Website | bms.com ↗ |
| Phone | 13026587581 |
| Employees | 32,500 |
| Revenue | $12.97B |
| Gross Profit | $9.25B |
| Net Income | $3.32B |
| Free Cash Flow | $11.44B |
| Total Assets | $87.63B |
| Total Liabilities | $65.32B |
| Equity | $22.32B |
About Bristol-Myers Squibb Company
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Bristol-Myers Squibb Company is a publicly traded company under the ticker symbol BMY on the NEW YORK STOCK EXCHANGE, INC., operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
34 analysts (2026-11-01)
📰 Latest News for BMY
While pharma peers stumble, AbbVie defeated the patent cliff
Xenon Pharmaceuticals Q3 Earnings Call Highlights
Bristol Myers Squibb (BMY) Reports 56 Week Pediatric Phase 3 Camzyos Data
5 Defensive Dividend Stocks Yielding Up to 8.7% for Retirement Income
Will Bristol Myers' Growth Brands Offset Eliquis Headwinds?
MRK's 2027 Outlook Challenging, Long-Term Prospects Promising
What Happens To Pfizer Stock If Patent Losses Outpace New Drugs?

